PIAS3 Antibody

What is PIAS3 and why is it important in signaling research?

PIAS3 (Protein Inhibitor of Activated STAT3) functions as a negative regulator of STAT3 transcriptional activity, making it a critical molecule in various signaling pathways. PIAS3 affects cellular processes by binding to activated STAT3, thereby inhibiting its DNA binding activity and subsequent transcriptional activation. This negative regulatory mechanism appears to be concentration-dependent, with increasing intracellular levels of PIAS3 proportionally enhancing the inhibitory effect on STAT3 signal transduction . The importance of PIAS3 has been demonstrated across multiple disease models, including lung cancer where approximately 50% of human NSCLC specimens show downregulation of PIAS3, suggesting its potential role as a tumor suppressor . Understanding PIAS3 function is critical for researchers working on cancer biology, inflammatory responses, and growth factor signaling.

What are the recommended protocols for using PIAS3 antibody in Western Blotting?

For optimal Western Blotting results with PIAS3 antibody, researchers should follow these methodological approaches:

• Sample preparation: Prepare cellular lysates using standard protocols with protease inhibitors to prevent protein degradation.

• Protein separation: Load 20-50 μg of protein per lane on SDS-PAGE gels (8-12% recommended).

• Transfer: Use PVDF or nitrocellulose membranes for protein transfer.

• Blocking: Block membranes with 5% non-fat dry milk or BSA in TBST for 1 hour at room temperature.

• Primary antibody incubation: Dilute PIAS3 antibody 1:1000 in blocking buffer and incubate overnight at 4°C .

• Detection: Use appropriate secondary antibodies and detection methods based on your imaging system.

When analyzing results, expect to detect PIAS3 at approximately 65-75 kDa . The antibody shows reactivity across human, mouse, rat, and monkey samples, making it versatile for comparative studies across species .

What controls should be included when working with PIAS3 antibody?

When designing experiments with PIAS3 antibody, include the following controls to ensure experimental validity:

• Positive control: Use cell lines known to express endogenous PIAS3 (e.g., A549 or H520 lung cancer cells) .

• Negative control: Include samples from PIAS3 knockout models or cells with PIAS3 knockdown.

• Loading control: Employ housekeeping proteins like GAPDH for whole cell lysates or hsnf2H for nuclear extracts .

• Specificity control: Consider using competing peptides or multiple PIAS3 antibodies targeting different epitopes.

• Subcellular fractionation controls: When studying nuclear translocation, include markers for nuclear (e.g., lamin B) and cytoplasmic (e.g., tubulin) fractions.

These controls help validate antibody specificity and ensure that observed changes in PIAS3 levels or localization are biologically meaningful rather than technical artifacts.

How can researchers effectively study PIAS3-STAT3 complex formation in response to growth factor stimulation?

To investigate the dynamic formation of PIAS3-STAT3 complexes following growth factor stimulation, researchers should implement a multi-technique approach:

• Co-immunoprecipitation (Co-IP): Use anti-PIAS3 antibody for immunoprecipitation followed by immunoblotting with anti-STAT3 antibody. This approach can detect complex formation within minutes after EGF stimulation .

• Time-course analysis: Design experiments with multiple time points (0, 5, 10, 30 minutes) after growth factor stimulation to capture the dynamic nature of complex formation and dissociation .

• Confocal microscopy: Employ immunofluorescence with specific antibodies against PIAS3 and STAT3 to visualize co-localization and nuclear translocation.

• Mutation studies: Compare wild-type STAT3 with Y705F mutants to assess the importance of specific phosphorylation sites in complex formation. Research shows that Y705 residue is critical for complete association of STAT3 with PIAS3 .

• Subcellular fractionation: Separate nuclear and cytoplasmic fractions at different time points to track the movement of the PIAS3-STAT3 complex between cellular compartments.

Data from lung cancer models demonstrate that PIAS3-STAT3 complexes form rapidly (within 5 minutes) after EGF stimulation, followed by nuclear translocation, with PIAS3 returning to the cytoplasm after approximately 30 minutes .

How does PIAS3 concentration affect STAT3 phosphorylation and transcriptional activity?

The relationship between PIAS3 concentration and STAT3 activity follows a dose-dependent pattern that can be experimentally demonstrated through these methodological approaches:

• Transfection with increasing amounts of PIAS3 expression vector: Transfect cells with graduated amounts of PIAS3-containing plasmid (e.g., pCMV vector) .

• Luciferase reporter assays: Co-transfect cells with a luciferase reporter construct containing STAT3 binding sequences to measure transcriptional activity.

• Western blotting for phospho-STAT3: Analyze nuclear extracts with anti-phosphospecific pSTAT3 antibody (targeting Y705) to assess phosphorylation status.

Experimental data from both A549 and H520 lung cancer cell lines demonstrate that increasing concentrations of PIAS3 result in:

• Proportional decrease in STAT3 transcriptional activity as measured by luciferase assays

• Dose-dependent reduction of phosphorylated STAT3 protein levels in the nucleus

This concentration-dependent inhibition occurs through two potential mechanisms:

• Decreasing STAT3 DNA binding activity

• Reducing the amount of phosphorylated STAT3 in the nucleus

These findings suggest that upregulation of PIAS3 could be explored as a potential antitumor strategy in cancers with constitutively active STAT3 signaling.

What are the methodological approaches for studying PIAS3 nuclear-cytoplasmic shuttling?

To effectively investigate PIAS3 nuclear-cytoplasmic shuttling, researchers should employ the following techniques:

• Live-cell imaging: Transfect cells with fluorescently tagged PIAS3 constructs to monitor real-time movement between cellular compartments.

• Subcellular fractionation: Prepare nuclear and cytoplasmic fractions at different time points after stimulation (e.g., with EGF) and analyze PIAS3 distribution by Western blotting.

• Immunofluorescence microscopy: Fix cells at various time points after stimulation and stain with anti-PIAS3 antibody to visualize localization changes.

• Nuclear export/import inhibitors: Use Leptomycin B (nuclear export inhibitor) or other inhibitors to block specific transport mechanisms and determine their role in PIAS3 shuttling.

• Mutation analysis: Create PIAS3 constructs with mutations in potential nuclear localization signals (NLS) or nuclear export signals (NES) to identify sequences essential for shuttling.

Research shows that in lung cancer cell models, PIAS3 shuttling follows a specific time course after EGF stimulation, with nuclear translocation occurring within 5-10 minutes and return to the cytoplasm by 30 minutes . This dynamic movement correlates with STAT3 activation and suggests that the PIAS3-STAT3 complex translocates as a unit, with subsequent dissociation and cytoplasmic redistribution of PIAS3.

What are the common pitfalls when detecting PIAS3 in experimental systems?

When working with PIAS3 antibody, researchers may encounter several technical challenges:

• Detection sensitivity issues:

  • The endogenous PIAS3 levels may vary significantly between cell types and experimental conditions.

  • Recommendation: Use at least 30-50 μg of total protein for Western blotting and optimize exposure times.

• Multiple band detection:

  • PIAS3 may appear as multiple bands between 65-75 kDa due to post-translational modifications .

  • Recommendation: Validate specific bands using positive controls and PIAS3 overexpression/knockdown experiments.

• Nuclear extraction efficiency:

  • When studying nuclear translocation, incomplete nuclear extraction may lead to misleading results.

  • Recommendation: Verify extraction efficiency with nuclear markers and optimize extraction protocols for your specific cell type.

• Antibody cross-reactivity:

  • Some antibodies may cross-react with other PIAS family members.

  • Recommendation: Validate antibody specificity using recombinant PIAS proteins or knockout models.

• Time-dependent changes:

  • The dynamic nature of PIAS3 localization requires careful timing of experiments.

  • Recommendation: Include multiple time points in your experimental design to capture the complete picture of PIAS3 dynamics.

How can researchers effectively study the interplay between PIAS3, MITF, and STAT3?

The three-way interaction between PIAS3, MITF, and STAT3 represents a complex regulatory network that requires careful experimental design:

• Sequential immunoprecipitation:

  • First immunoprecipitate with anti-MITF antibodies followed by immunoblotting with anti-PIAS3 antibody to detect MITF-PIAS3 complexes.

  • Re-probe with anti-STAT3 antibodies to identify potential three-way complexes .

• Mutational analysis:

  • Compare wild-type MITF with mutants unable to bind PIAS3.

  • Assess how these mutations affect both MITF and STAT3 transcriptional activities .

• Transcriptional activity measurements:

  • Use rtPCR to measure mRNA levels of both MITF and STAT3 target genes at different time points after activation (e.g., 30 minutes and 4 hours) .

  • Complement with luciferase reporter assays specific for each transcription factor.

• Computational modeling:

  • Develop quantitative models to understand the dynamic interplay between these factors.

  • Current models suggest that simple competitive binding may not fully explain experimental observations .

What approaches should be used to distinguish between direct and indirect effects of PIAS3 on signaling pathways?

Distinguishing direct from indirect PIAS3 effects requires methodological rigor:

• Structure-function analysis:

  • Generate PIAS3 deletion or point mutants that specifically disrupt interactions with particular proteins.

  • Test these mutants in functional assays to determine which domains are essential for specific effects.

• In vitro binding assays:

  • Use purified recombinant proteins to test direct interactions in a controlled environment.

  • Complement with surface plasmon resonance (SPR) or isothermal titration calorimetry (ITC) for quantitative binding parameters.

• Temporal analysis:

  • Examine the kinetics of PIAS3 interactions, phosphorylation events, and transcriptional responses.

  • Direct effects typically occur rapidly (minutes), while indirect effects may take longer (hours).

• Proximity ligation assays:

  • Use this technique to visualize and quantify protein interactions in situ.

  • This can help establish direct physical associations between PIAS3 and potential partners.

• ChIP-seq analysis:

  • Determine whether PIAS3 directly associates with chromatin at STAT3 binding sites.

  • This helps distinguish between cytoplasmic inhibition and nuclear inhibition mechanisms.

Research suggests that PIAS3 has both direct effects on STAT3 DNA binding and indirect effects through modulating phosphorylation status . The dose-dependent relationship between PIAS3 levels and decreased nuclear phospho-STAT3 indicates a potential direct effect on STAT3 activation or nuclear retention .

How should researchers interpret changes in PIAS3-STAT3 binding in response to different stimuli?

When analyzing PIAS3-STAT3 binding data across experimental conditions, consider these interpretative approaches:

• Stimulus-specific responses:

  • Different stimuli (e.g., EGF, IL-6, oncogenic mutations) may induce distinct patterns of PIAS3-STAT3 binding.

  • Compare binding kinetics, magnitude, and duration across stimuli to identify pathway-specific regulation.

• Correlation with phosphorylation status:

  • Analyze STAT3 Y705 phosphorylation in parallel with PIAS3 binding.

  • Data shows that Y705 phosphorylation is important for complete association of STAT3 with PIAS3 .

• Subcellular compartment analysis:

  • Interpret binding data in the context of subcellular localization.

  • The same binding event may have different functional consequences depending on whether it occurs in the cytoplasm or nucleus.

• Time course interpretation:

  • The timing of PIAS3-STAT3 complex formation and dissociation provides insights into regulatory mechanisms.

  • In EGF-stimulated cells, complex formation occurs rapidly followed by nuclear translocation within 5-10 minutes .

• Quantitative analysis:

  • Calculate binding ratios and correlation coefficients between PIAS3 binding and functional outcomes.

  • This can help establish whether the relationship is linear or involves threshold effects.

Research in lung cancer models demonstrates that mutation of STAT3 Y705 to phenylalanine significantly decreases PIAS3-STAT3 binding despite EGF stimulation, indicating this residue's importance in the interaction mechanism .

What are the key considerations when designing experiments to study the effect of PIAS3 on gene expression?

To effectively study PIAS3-mediated regulation of gene expression:

• Target gene selection:

  • Choose a panel of known STAT3 target genes with varying sensitivity to STAT3 activation.

  • Include both immediate-early and delayed-response genes to capture temporal effects.

• Experimental design for causality:

  • Use both overexpression and knockdown/knockout approaches for PIAS3.

  • Compare wild-type PIAS3 with functional mutants to identify domain-specific effects.

• Time course considerations:

  • Sample at multiple time points (e.g., 30 minutes, 2 hours, 4 hours, 24 hours) to capture both direct and indirect effects on transcription.

  • Research shows differences in transcriptional effects at 30 minutes versus 4 hours after activation .

• Controls for specificity:

  • Include genes regulated by other transcription factors to confirm STAT3 pathway specificity.

  • Use STAT3 inhibitors or dominant-negative STAT3 constructs as controls.

• Integrative analysis:

  • Combine transcriptomic data with ChIP-seq or ChIP-qPCR to correlate gene expression changes with STAT3 binding.

  • Integrate phospho-proteomic data to link signaling events with transcriptional outcomes.

Research demonstrates that PIAS3 has a dose-dependent inhibitory effect on STAT3 transcriptional activity, which can be measured using luciferase reporter assays containing STAT3 binding sequences . This suggests that varying PIAS3 levels experimentally allows for fine-tuning of STAT3-mediated gene expression.

How can PIAS3 antibody be used to explore potential therapeutic applications in cancer research?

PIAS3 antibody can support cancer therapeutic research through these advanced applications:

• Biomarker development:

  • Quantify PIAS3 protein levels in tumor samples versus normal tissues.

  • Research indicates approximately 50% of NSCLC specimens show downregulation of PIAS3 .

  • Correlate PIAS3 levels with clinical outcomes and treatment responses.

• Target validation studies:

  • Use PIAS3 antibody to confirm target engagement by compounds designed to modulate PIAS3-STAT3 interactions.

  • Evaluate changes in PIAS3 expression or localization in response to experimental therapies.

• Combination therapy research:

  • Assess how standard therapies affect PIAS3-STAT3 dynamics.

  • Explore whether PIAS3 upregulation sensitizes resistant tumors to existing treatments.

• Mechanistic studies:

  • Investigate how PIAS3 concentration-dependent inhibition of STAT3 could be leveraged therapeutically.

  • Experimental data shows a clear dose-dependent relationship between PIAS3 levels and inhibition of STAT3 phosphorylation and transcriptional activity .

• Development of PIAS3 mimetics:

  • Use structural insights from PIAS3-STAT3 binding studies to design peptides or small molecules that mimic PIAS3 inhibitory function.

  • Validate these approaches using PIAS3 antibody to compare mechanisms of action.

The concentration-dependent inhibitory effect of PIAS3 on STAT3 activity suggests that strategies to upregulate endogenous PIAS3 or provide functional PIAS3 mimetics could represent promising therapeutic approaches in cancers with constitutively active STAT3 signaling .

What are the methodological approaches for studying PIAS3 in patient-derived samples?

When investigating PIAS3 in clinical specimens, researchers should consider these specialized approaches:

• Tissue preservation and processing:

  • Optimize fixation protocols to preserve PIAS3 epitopes for immunohistochemistry.

  • For fresh samples, rapidly process for protein extraction to prevent degradation.

• Immunohistochemistry optimization:

  • Test multiple antibody dilutions (starting with 1:100 to 1:500).

  • Compare detection methods (DAB versus fluorescent) for sensitivity.

  • Include positive and negative control tissues with known PIAS3 expression patterns.

• Quantitative analysis of expression:

  • Use digital pathology approaches to quantify PIAS3 levels.

  • Consider multiplexed immunofluorescence to simultaneously evaluate PIAS3, phospho-STAT3, and other pathway components.

• Correlation with genomic data:

  • Integrate PIAS3 protein expression data with genomic alterations in the STAT3 pathway.

  • Analyze associations with mutations that may affect PIAS3-STAT3 interactions.

• Ex vivo functional studies:

  • Establish primary cell cultures or patient-derived xenografts to study dynamic PIAS3 regulation.

  • Test how patient-derived cells with varying PIAS3 levels respond to STAT3 pathway stimulation or inhibition.

Research in lung cancer has demonstrated that PIAS3 downregulation occurs in approximately 50% of NSCLC specimens, with similar patterns observed in glioblastoma multiforme . This suggests PIAS3 evaluation may have broader relevance across multiple cancer types with STAT3 pathway activation.

How can researchers design experiments to resolve contradictory findings regarding PIAS3 function?

To address contradictory results in PIAS3 research, implement these rigorous approaches:

• Cell type-specific analysis:

  • Compare PIAS3 function across multiple cell types within the same experimental framework.

  • Standardize key variables (protein expression levels, stimulation conditions, readout assays).

• Context-dependent regulation:

  • Systematically vary experimental conditions (serum levels, cell density, matrix composition).

  • Test how these contextual factors influence PIAS3 function and localization.

• Temporal resolution:

  • Implement high-resolution time course studies to capture dynamic changes.

  • Current research shows PIAS3 nuclear translocation occurs within minutes of EGF stimulation, with return to cytoplasm by 30 minutes .

  • Contradictory findings may result from sampling at different time points.

• Quantitative modeling:

  • Develop mathematical models incorporating known interactions and rate constants.

  • Use these models to identify parameter ranges that could explain apparently contradictory observations.

  • Research suggests current models cannot fully explain all experimental observations regarding MITF-PIAS3-STAT3 interactions .

• Integrated multi-omics approach:

  • Combine proteomic, phospho-proteomic, and transcriptomic analyses.

  • Identify additional pathway components that may explain context-dependent effects.